Disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to treatment with an anti-HER2 therapy and administering to the patient a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell a nucleic acid molecule bound to the polypeptide sequence via electrostatic interactions and a chemical agent non- covalently linked to the nucleic acid sequence. Also disclosed are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with the drug delivery molecule. Further disclosed herein are methods of treating cancer in a patient, the method comprising identifying a patient who is resistant to anti-HER2 therapy and administering to the patient a therapeutically effective amount of a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell and a sulfonated corrole molecule bound to the polypeptide sequence. Finally disclosed herein are methods of inducing apoptosis in an anti-HER2 therapy resistant HER2+ breast cancer cell, the method comprising contacting the anti-HER2 therapy resistant HER2+ breast cancer cell with a drug delivery molecule, comprising a polypeptide molecule adapted to target and/or penetrate a type of cell and a sulfonated corrole molecule bound to the polypeptide sequenceLa présente invention concerne des méthodes de traitement du cancer chez un patient, lesdites méthodes comprenant les étapes suivantes : identification dun patient résistant à un traitement utilisant une thérapie anti-HER2 et administration audit patient dune molécule dadministration de médicament, comprenant une molécule de polypeptide conçue pour cibler et/ou pénétrer un type de cellule, une molécule dacide nucléique liée à la séquence polypeptidique par lintermédiaire dinteractions électrostatiques
